SynthesisNeurosurgical review2026
Repeat stereotactic radiosurgery for pituitary adenomas: a systematic review and meta-analysis.
Synthesis in Neurosurgical review, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Repeat stereotactic radiosurgery (SRS) is used for pituitary adenomas (PAs), yet long-term safety and efficacy remain incompletely defined. This systematic review and meta-analysis evaluated radiological control, endocrine outcomes, and adverse effects following repeat SRS. A systematic search of PubMed, Scopus, Web of Science, and Embase was conducted from inception through November 2025. Studies reporting outcomes after repeat SRS for PAs were included. Five studies involving 114 patients were included. The pooled tumor control (TC) rate was 76% (95% CI: 67–84%). Five-year PFS was 75% (95% CI: 29–100%), and 10-year PFS was 60% (95% CI: 49–72%). Endocrine remission (ER) among functioning tumors occurred in 51% (95% CI: 36–67%). New hypopituitarism, adrenal-axis deficit, thyroid-axis deficit, visual deficit, and cranial nerve deficit occurred in 19% (95% CI: 0–74%), 10% (95% CI: 2–22%), 7% (95% CI: 1–18%), 7% (95% CI: 3–12%), and 6% (95% CI: 1–12%), respectively. Adverse radiation events (AREs) occurred in 8% (95% CI: 3–16%). Radiation-induced optic neuropathy (RION) remained extremely rare at 0% (95% CI: 0–2%), and all-cause mortality after repeat SRS was 3% (95% CI: 0–8%). Repeat SRS demonstrates durable radiological control and moderate endocrine efficacy with low rates of severe toxicity, supporting its role as an effective salvage option for selected patients with PAs. However, the evidence is limited by small sample sizes and heterogeneity in reporting, and future multicenter prospective studies are needed to refine patient selection and optimize treatment strategies.
Indexed as
Identifiers
41766020What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.